Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope

This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.



Project LeadsEmails

Mary Nilsson (Eli Lilly)

nilsson_mary_e@lilly.com

William Palo (Abbvie)

william.palo@abbvie.com

Katie Warren (PHUSE Project Assistant)katie@phuse.global


Objectives & Deliverables 

Timelines 

Project team review final White Paper 

Q2 2023
PHUSE Steering Committee & Public Review Q3 2023
Publish White PaperQ4 2023


Status
colourBlue
titleCurrent Status
Q1 2023

Working on a White Paper



Project MembersOrganisation
Alan ShapiroFDA
Beilei XuSanofi
Carolyn SetzeAbbVie
Cathy BezekAstellas
Charles BeasleyMNS
Elisa YoungSouthern Star Research
James GaiserPrometrika
Joanne ZhouGSK
Jon HaddadGSK
Jun LiSanofi
Kim MusgraveAmgen



Project MembersOrganisation

Kirthi Rangaraju

Pfizer
Laura GoebelJanssen Research & Development
Melvin MunsakaAbbVie
Meredith ChuckFDA
Monali Desai Alkermes 
Nancy BruckenCSG
Pranab MitraIndustry
Raj PhadtareCorvus Pharma
Ramaiah MuvvalaInductive Quotient Analytics
Robert (Mac) GordonJanssen Research & Development
Russell NewhouseEli Lilly
Shraddha GanooICON plc
Simin K BayganiEli Lilly
Tejas PatelBooz Allen Hamilton
Tiffany Davis Gillead